<DOC>
	<DOCNO>NCT01732913</DOCNO>
	<brief_summary>This study evaluate effect addition idelalisib ( GS-1101 ) rituximab progression-free survival ( PFS ) adults previously treat indolent non-Hodgkin lymphoma ( iNHL ) .</brief_summary>
	<brief_title>Efficacy Safety Idelalisib ( GS-1101 ) Combination With Rituximab Previously Treated Indolent Non-Hodgkin Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm diagnosis Bcell iNHL , histological subtype limit follow : 1 . Follicular lymphoma ( FL ) Grade 1 , 2 , 3a 2 . Small lymphocytic lymphoma ( SLL ) absolute lymphocyte count &lt; 5 x 10^9/L time diagnosis 3 . Lymphoplasmacytoid lymphoma/Waldenstr√∂m macroglobulinemia ( LPL/WM ) 4 . Marginal zone lymphoma ( MZL ) ( splenic , nodal , extranodal ) History lymphoid malignancy allow per inclusion criterion Ongoing druginduced liver injury , active hepatitis C , active hepatitis B , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , extrahepatic obstruction cause cholelithiasis , cirrhosis liver , portal hypertension . Received previous treatment rituximab effective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>iNHL</keyword>
	<keyword>indolent NHL</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>CAL-101</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Small lymphocytic lymphoma</keyword>
	<keyword>lymphoplasmacytoid lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>LPL</keyword>
	<keyword>WM</keyword>
	<keyword>Marginal zone lymphoma</keyword>
	<keyword>MZL</keyword>
	<keyword>SLL</keyword>
	<keyword>FL</keyword>
	<keyword>GS-1101</keyword>
	<keyword>idelalisib</keyword>
</DOC>